	US 12,404,331 B2
	Anti-PD-1 antibodies and uses thereof
Wei-Wu He, Sugarland, TX (US); Paul Bryson, Alhambra, CA (US); Si Li, Alhambra, CA (US); and Donghui Ma, North Potomac, MD (US)
Assigned to TCRCURE BIOPHARMA CORP.; and GUANGDONG TCRCURE BIOPHARMA TECHNOLOGY CO., LTD., Guangzhou (CN)
Appl. No. 17/604,555
Filed by TCRCURE BIOPHARMA CORP., Chapel Hill, NC (US); and GUANGDONG TCRCURE BIOPHARMA TECHNOLOGY CO., LTD., Guangzhou (CN)
PCT Filed Apr. 17, 2020, PCT No. PCT/US2020/028773 § 371(c)(1), (2) Date Oct. 18, 2021, PCT Pub. No. WO2020/214957, PCT Pub. Date Oct. 22, 2020.
Claims priority of provisional application 62/836,177, filed on Apr. 19, 2019.
Prior Publication US 2022/0195047 A1, Jun. 23, 2022
Int. Cl. C07K 16/28 (2006.01); A61K 39/39 (2006.01); A61K 45/06 (2006.01); A61K 47/68 (2017.01)

CPC C07K 16/2818 (2013.01) [A61K 39/39 (2013.01); A61K 45/06 (2013.01); A61K 47/6849 (2017.08); C07K 2317/24 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/73 (2013.01); C07K 2317/92 (2013.01)]

28 Claims

1. An antibody or antigen-binding fragment thereof that binds to PD-1

(Programed Cell Death Protein 1) comprising:

a heavy chain variable region (VH) comprising complementarity determining regions (CDRs) 1, 2, and 3, wherein the VH CDR1 region comprises an amino acid sequence that is identical to a selected VH CDR1 amino acid sequence, the VH CDR2 region comprises an amino acid sequence that is identical to a selected VH CDR2 amino acid sequence, and the VH CDR3 region comprises an amino acid sequence that is % identical to a selected VH CDR3 amino acid sequence; and

a light chain variable region (VL) comprising CDRs 1, 2, and 3, wherein the VL CDR1 region comprises an amino acid sequence that is identical to a selected VL CDR1 amino acid sequence, the VL CDR2 region comprises an amino acid sequence that is identical to a selected VL CDR2 amino acid sequence, and the VL CDR3 region comprises an amino acid sequence that is identical to a selected VL CDR3 amino acid sequence,

wherein the selected VH CDRs 1, 2, and 3 amino acid sequences and the selected VL CDRs, 1, 2, and 3 amino acid sequences are one of the following:

(1) the selected VH CDRs 1, 2, 3 amino acid sequences are set forth in SEQ ID NOs: 8, 9, 10, respectively, and the selected VL CDRs 1, 2, 3 amino acid sequences are set forth in SEQ ID NOs: 5, 6, 7, respectively;

(2) the selected VH CDRs 1, 2, 3 amino acid sequences are set forth in SEQ ID NOs: 22, 23, 24, respectively, and the selected VL CDRs 1, 2, 3 amino acid sequences are set forth in SEQ ID NOs: 19, 20, 21, respectively;

(3) the selected VH CDRs 1, 2, 3 amino acid sequences are set forth in SEQ ID NOs: 74, 75, 76, respectively, and the selected VL CDRs 1, 2, 3 amino acid sequences are set forth in SEQ ID NOs: 71, 72, 73, respectively; and

(4) the selected VH CDRs 1, 2, 3 amino acid sequences are set forth in SEQ ID NOs: 34, 35, 36, respectively, and the selected VL CDRs 1, 2, 3 amino acid sequences are set forth in SEQ ID NOs: 31, 32, 33, respectively.